Desmopressin DDAVP

An FDA-approved hormone medication used for excessive thirst and urination from a rare condition, for bedwetting, and for certain bleeding disorders. Human studies strongly support these uses, though it can cause dangerously low blood sodium if overused.

Also known as DDAVP, Minirin, Desmopresina, Desmopressine, Desmopressinum, 1-Deamino-8-D-arginine vasopressin, 1-Desamino-8-D-arginine vasopressin, ENR1LLB0FP, Deamino Arginine Vasopressin

Effects Hormonal

Routes Nasal Oral

Legal status Prescription drug

WADA Banned at all times

Molecular Structure of C₄₆H₆₄N₁₄O₁₂S₂

Drag to rotate · scroll to zoom

PubChem has no 3D conformer for this molecule, so this is the flat structure.

Chemistry

Formula: C46H64N14O12S2
Molar mass: 1069.2
CAS: 16679-58-6
PubChem CID: 5311065
IUPAC name: (2S)-N-[(2R)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]-1-[(4R,7S,10S,13S,16S)-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]pyrrolidine-2-carboxamide
InChIKey: NFLWUMRGJYTJIN-PNIOQBSNSA-N

Reported dosing

Approved label

What has been reported in the literature and by users. This is a record of what is done, not a recommendation.

Typical dose 0.1-0.4 mg/day (oral) or 10-40 mcg/day (intranasal)

Reported range Varies widely by indication (diabetes insipidus, bedwetting, bleeding disorders)

Route Oral, intranasal, or injection

Frequency 1-3 times daily

Duration Chronic/ongoing (as prescribed) or single-dose (procedural use)

FDA-approved prescription medication (DDAVP); dosing is highly indication-specific and requires monitoring for water retention/hyponatremia.

Where this comes from FDA prescribing information

These figures are recorded for reference and are not a recommendation. Dosing is a decision for you and a clinician.